BioSpace News Archive

BioMidwest

Lilly’s tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks

Eli Lilly and Company announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis.

June 8, 2024
·
18 min read
Biotech Bay

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024

Jaguar Health, Inc. announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units to one new employee.

June 8, 2024
·
3 min read
Biotech Bay

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Akero Therapeutics, Inc. announced two presentations featuring its lead product candidate efruxifermin at the European Association for the Study of the Liver Congress 2024, in Milan, Italy.

June 8, 2024
·
9 min read
Drug Development

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

4D Molecular Therapeutics presented supplemental aflibercept injection-free subgroup analyses of the previously reported 24-week landmark results from the randomized Dose Expansion cohort from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration patients with severe disease activity and a high treatment burden.

June 8, 2024
·
7 min read